ArticleScientific reports2025
Design and characterization of anti-microbial novel herbal nanofiber scaffolds for the management of periodontal diseases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of Drynaria rhizome in-situ gel in periodontitis management.Bioinformation · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Design and evaluation of PCL and gelatin loaded nanofiber containing herbal formulation named Ashvakatri in the treatment of chronic periodontitis. The electro-spinning method was used to create the composite nano-fibers containing herbal formulation, which were then evaluated for various parameters including in-vitro antimicrobial study and in-vitro drug release. An interconnected, continuous and bead free nanofiber with an average diameter of 150–250 nm was exhibited by the optimized nanofiber. The addition of gelatin and PCL to the optimized nanofiber improved its biocompatibility and bioadhesive characteristics. According to anti-microbial investigation and CLSM study indicated the remarkable inhibition of periodontal pathogens such as Aggregabacter actinomycetemcomitans (AI), Porphyromonas Gingivilis (PG), Fusobacterium spp (FB), and Porphyromonas intermedia (PI) respectively by optimized nanofiber and in-vitro drug release study also demonstrated the controlled release of composite nanofiber for over 220 h. Additionally, the MTT assay and in-vitro scratch assay indicated the composite NF had no cytotoxicity to the fibroblast cell line. The fabricated NF is a potential option for chronic periodontitis treatment since it expedited anti-bacterial, cytotoxic and sustained release medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.